Quick Answer
Annovis Bio, Inc. reported Cash and Equivalents of $19.53 million for fiscal year 2025.
Annovis Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $19.53M | +85.1% |
| 2024 | $10.55M | +83.4% |
| 2023 | $5.75M | -79.7% |
| 2022 | $28.38M | -11.3% |
| 2022 | $31.99M | -11.1% |
| 2022 | $35.97M | -15.7% |
| 2022 | $42.67M | -6.6% |
| 2021 | $45.69M | +465.8% |
| 2020 | $8.07M | +434488.7% |
| 2019 | $1.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.29M | +21.0% | -10.8% |
| June 30, 2025 | $17.13M | +328.5% | -23.0% |
| March 31, 2025 | $22.24M | +608.8% | +110.7% |
| December 31, 2024 | $10.55M | +83.4% | -16.5% |
| September 30, 2024 | $12.64M | +98.8% | +216.1% |
| June 30, 2024 | $4.00M | -74.6% | +27.4% |
| March 31, 2024 | $3.14M | -81.3% | -45.5% |
| December 31, 2023 | $5.75M | -79.7% | -9.4% |
- Annovis Bio, Inc. showed an increase of +85.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Annovis Bio, Inc.’s cash and equivalents has grown by 1051156.1% (from $1.9 thousand to $19.53 million).
- The most recent figure is from Annovis Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: